Author Topic: 1st PML case with ocrelizumab alone reported  (Read 63 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
1st PML case with ocrelizumab alone reported
« on: April 30, 2020, 02:57:17 pm »
The first clear-cut case of PML in an MS patient taking Ocrevus has been reported--and the patient (age 78) died. Sad news indeed. From Medscape Neurology (April 30, 2020), "Report Details First Case of PML with Ocrelizumab Alone":


https://www.medscape.com/viewarticle/929728
« Last Edit: April 30, 2020, 02:58:58 pm by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
Re: 1st PML case with ocrelizumab alone reported
« Reply #1 on: April 30, 2020, 03:08:16 pm »
Here is the abstract of the report mentioned in the article cited in the previous post.


AAN abstract (2020--exact date not given), "Progressive multifocal leukoencephalopathy in a patient on ocrelizumab monotherapy":



https://index.mirasmart.com/AAN2020/PDFfiles/AAN2020-004875.html


The last sentence of the Conclusions section might be worth noting:


Quote
This case emphasizes the importance of a thorough discussion of the risks and benefits of ocrelizumab, especially in patients at higher risk for infections, such as the elderly.
« Last Edit: April 30, 2020, 03:53:06 pm by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
A paper prompted by this case (apparently) was presented to the AAN (American Academy of Neurology), which has scheduled virtual presentations of research papers in May and June instead of its usual annual meeting, which was canceled on account of COVID-19.  This is the abstract of the paper, "Evaluation of risk factors in developing lymphopenia and hypogammaglobulinemia in anti-CD20 treated multiple sclerosis patients":


https://index.mirasmart.com/AAN2020/PDFfiles/AAN2020-005218.html
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
2 Replies
328 Views
Last post December 26, 2016, 02:47:31 pm
by agate
0 Replies
111 Views
Last post January 29, 2018, 06:40:19 pm
by agate
0 Replies
64 Views
Last post January 30, 2018, 02:41:55 pm
by agate
6 Replies
79 Views
Last post March 25, 2019, 10:13:43 am
by agate
0 Replies
8 Views
Last post May 18, 2020, 04:38:30 pm
by agate